Krystal Biotech
KRYS
368 hedge funds and large institutions have $7.32B invested in Krystal Biotech in 2026 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 138 increasing their positions, 105 reducing their positions, and 36 closing their positions.
155% more call options, than puts
Call options by funds: $81M | Put options by funds: $31.8M
111% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 36
31% more repeat investments, than reductions
Existing positions increased: 138 | Existing positions reduced: 105
25% more funds holding in top 10
Funds holding in top 10: 8 → 10 (+2)
10% more funds holding
Funds holding: 334 → 368 (+34)
5% more capital invested
Capital invested by funds: $7.01B → $7.32B (+$318M)
0.95% less ownership
Funds ownership: 98.03% → 97.07% (-0.95%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$56.4M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$50.9M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$28M |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
+$21.2M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$102M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$30.7M |
| 3 |
Goldman Sachs
New York
|
-$20.9M |
| 4 |
Barclays
London,
United Kingdom
|
-$14.7M |
| 5 |
O
OrbiMed
New York
|
-$13.5M |
KRYS Hedge Fund Activity: Q1 2026 in Review
368 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2026, worth a combined $7.32B — up 4.5% from $7.01B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new KRYS positions and 36 closed out — a net gain of 40 holders — while 138 added to existing stakes and 105 trimmed.
The largest buyer was Soleus Capital Management, adding an estimated $56.4M. The largest seller was Citadel Advisors, cutting an estimated $102M.
- 368 institutional investors held Krystal Biotech (KRYS) as of Q1 2026, up from 334 in Q4 2025.
- Funds reported $7.32B of Krystal Biotech stock for Q1 2026, up 4.5% quarter-over-quarter.
- 76 funds opened new Krystal Biotech positions in Q1 2026 and 36 closed out, a net change of +40 holders.
- The largest Krystal Biotech buyer in Q1 2026 was Soleus Capital Management, an estimated $56.4M added.
- The largest Krystal Biotech seller in Q1 2026 was Citadel Advisors, an estimated $102M sold.
Based on aggregated 13F filings for Q1 2026.